Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs. 1991

D K Olivero, and M G Davidson, and R V English, and M P Nasisse, and V E Jamieson, and T M Gerig
Department of Companion Animal and Special Species Medicine, College of Veterinary Medicine, North Carolina State University, Raleigh 27606.

Keratoconjunctivitis sicca (KCS) is a prevalent and often vision-threatening condition in dogs. In several reports, 2% cyclosporine (cyclosporin A, CsA) was described as effective in modulating the clinical signs of KCS. This study was designed to compare the efficacy of 1% CsA vs a placebo, using a randomized double-blind clinical trial. Topical administration of 1% CsA significantly improved Schirmer wetting values and subjective markers of corneal health as compared with the placebo. In the dogs treated with topical administration of 1% CsA, the clinical signs of KCS were improved in 81.8% of cases.

UI MeSH Term Description Entries
D007638 Keratoconjunctivitis Sicca Drying and inflammation of the conjunctiva as a result of insufficient lacrimal secretion. When found in association with XEROSTOMIA and polyarthritis, it is called SJOGREN'S SYNDROME. Sicca, Keratoconjunctivitis
D009883 Ophthalmic Solutions Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS. Eye Drop,Eyedrop,Eyedrops,Ophthalmic Solution,Eye Drops,Drop, Eye,Drops, Eye,Solution, Ophthalmic,Solutions, Ophthalmic
D004283 Dog Diseases Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used. Canine Diseases,Canine Disease,Disease, Canine,Disease, Dog,Diseases, Canine,Diseases, Dog,Dog Disease
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016572 Cyclosporine A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). Cyclosporin A,Ciclosporin,CsA-Neoral,CyA-NOF,Cyclosporin,Cyclosporine A,Neoral,OL 27-400,Sandimmun,Sandimmun Neoral,Sandimmune,CsA Neoral,CsANeoral,CyA NOF,OL 27 400,OL 27400

Related Publications

D K Olivero, and M G Davidson, and R V English, and M P Nasisse, and V E Jamieson, and T M Gerig
July 1989, The Cornell veterinarian,
D K Olivero, and M G Davidson, and R V English, and M P Nasisse, and V E Jamieson, and T M Gerig
October 1991, Journal of the American Veterinary Medical Association,
D K Olivero, and M G Davidson, and R V English, and M P Nasisse, and V E Jamieson, and T M Gerig
May 2012, Klinische Monatsblatter fur Augenheilkunde,
D K Olivero, and M G Davidson, and R V English, and M P Nasisse, and V E Jamieson, and T M Gerig
December 1995, Veterinary immunology and immunopathology,
D K Olivero, and M G Davidson, and R V English, and M P Nasisse, and V E Jamieson, and T M Gerig
January 1998, Advances in experimental medicine and biology,
D K Olivero, and M G Davidson, and R V English, and M P Nasisse, and V E Jamieson, and T M Gerig
June 2021, Veterinary world,
D K Olivero, and M G Davidson, and R V English, and M P Nasisse, and V E Jamieson, and T M Gerig
July 1995, American journal of veterinary research,
D K Olivero, and M G Davidson, and R V English, and M P Nasisse, and V E Jamieson, and T M Gerig
November 1995, The Veterinary record,
D K Olivero, and M G Davidson, and R V English, and M P Nasisse, and V E Jamieson, and T M Gerig
October 1992, American journal of ophthalmology,
D K Olivero, and M G Davidson, and R V English, and M P Nasisse, and V E Jamieson, and T M Gerig
September 2016, Acta veterinaria Hungarica,
Copied contents to your clipboard!